In this issue:
Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated CRC
Chemotherapy and biologic use in mCRC in Australia
Prognosis in microsatellite instability and/or mismatch repair deficiency stage III colon cancer
Cetuximab-induced skin toxicity and early tumour shrinkage in mCRC
Circulating-tumour DNA tracks MRD in localised colon cancer
Circulating cell-free DNA as a prognostic biomarker in mCRC
Bevacizumab as adjuvant treatment of colon cancer
Oxaliplatin-based adjuvant chemotherapy for rectal cancer
FOLFOXIRI + panitumumab for RAS wild-type mCRC
Molecular marker analysis of right- or left-sided primary CRC
Please login below to download this issue (PDF)